Gilead Statement on Favorable Verdict in HIV PrEP Patents Litigation

Foster City, Calif., May 9, 2023 – We are pleased with today’s favorable jury verdict in the Delaware District Court, in which Gilead won on all counts.  The jury determined that Gilead has not infringed the U.S. government’s patents and that the patents are invalid. The jury’s verdict recognizes Gilead’s commitment to transforming the lives of the communities we serve. Gilead is proud to have invented and developed Truvada^® and Descovy^®.  Today’s decision confirms our longstanding belief that we have always had the rights to make Truvada^® and Descovy^® for PrEP available to all who need it.  Gilead will continue to champion collaborations, including our efforts with the U.S. Health and Human Services Department (HHS) and Centers for Disease Control and Prevention (CDC) that span more than 15 years, as we all work together toward our common goal to end the HIV epidemic for everyone, everywhere.

About Gilead Sciences 
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, millions of people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.